Ousia - great post. Well thought out.
PI-88 Trials in Taiwan are a much more 'straightforward' proposition then the Multi Country Phase III undertaking.
Recruitment rates are very difficult to predict in terms of such global Trial. Liver Cancer is a much more prevalent disease in Asia as I understand matters, and therefore recruitment rates are more certain there.
A new dawn for Progen!
interesting times ahead, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PGL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $71.64M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 43.5¢ | 43.5¢ | $619.6K | 1.424M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 213388 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 108496 | 4 |
View Market Depth
| Last trade - 15.40pm 24/06/2024 (20 minute delay) ? |
| PGL (ASX) Chart |